tbuckley/cabot-search huggingface dataset:
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
Authors: Christoph Wanner, Hiddo J.L. Heerspink, Bernard Zinman, Silvio E. Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Stefan Hantel, Hans-Juergen Woerle, Uli C. Broedl, Maximilian von Eynatten, Per-Henrik Groop
Journal: Journal of the American Society of Nephrology (2018)

Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes.Participants (n=7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, or placebo added to standard of care. We calculated eGFR slopes using random-intercept/random-coefficient models for prespecified study periods: treatment initiation (baseline to week 4), chronic maintenance treatment (week 4 to last value on treatment), and post-treatment (last value on treatment to follow-up).Compared with placebo, empagliflozin was associated with uniform shifts in individual eGFR slopes across all periods. On treatment initiation, adjusted mean slope (eGFR change per week, ml/min per 1.73 m2) decreased with empagliflozin (-0.77; 95% confidence interval, -0.83 to -0.71; placebo: 0.01; 95% confidence interval, -0.08 to 0.10; P<0.001). However, annual mean slope (ml/min per 1.73 m2 per year) did not decline with empagliflozin during chronic treatment (empagliflozin: 0.23; 95% confidence interval, 0.05 to 0.40; placebo: -1.46; 95% confidence interval, -1.74 to -1.17; P<0.001). After drug cessation, the adjusted mean eGFR slope (ml/min per 1.73 m2 per week) increased and mean eGFR returned toward baseline level only in the empagliflozin group (0.56; 95% confidence interval, 0.49 to 0.62; placebo -0.02; 95% confidence interval, -0.12 to 0.08; P<0.001). Results were consistent across patient subgroups at higher CKD risk.The hemodynamic effects of empagliflozin, associated with reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function.
Let there be oxygen and T cells
Authors: Paul R. Walker
Journal: Journal of Clinical Investigation (2018)

The stroma of solid tumors can exclude or limit immune infiltration, or lead to the recruitment of tumor-promoting rather than tumor-attacking immune cells. This finding was reported by Jayaprakash et al. in this issue of the JCI, and it was particularly prominent in the hypoxic zones of tumors in the transgenic adenocarcinoma of the mouse prostate (TRAMP) cancer models. A current clinical goal of immune checkpoint blockade (ICB) is to extend its utility to more patients by converting immunologically "cold" tumors that do not provoke a strong immunological response to "hot" tumors that are invaded by swarms of T cells. When the underlying cause is hypoxia linked, the therapeutic combination of simultaneous targeting of hypoxia and immune checkpoints merits exploration in future clinical trials.
P3.16-20 Feasibility of Limited Resection for Peripheral Small-Sized Non-Small Cell Lung Cancer According to FDG Accumulation and Imaging Findings
Authors: M. Aragaki, K. Kaga, Y. Hida, T. Kato, R. Chiba, Y. Motohashi, Y. Matsui
Journal: Journal of Thoracic Oncology (2018)
Abstract 13474: Heparin-Induced Thrombocytopenia and In-Hospital Mortality in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
Authors: Toshiaki Isogai, Hiroki Matsui, Hiroyuki Tanaka, Kiyohide Fushimi, Hideo Yasunaga
Journal: Circulation (2016)

Introduction: Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening complication in patients with acute coronary syndrome (ACS). It remains unclear how the development of HIT aff...
Innovations in Ventricular Assist Devices for End-Stage Heart Failure
Authors: Robert J.H. Miller, Jeffrey J. Teuteberg, Sharon A. Hunt
Journal: Annual Review of Medicine (2018)

The number of patients with end-stage heart failure (HF) continues to increase over time, but there has been little change in the availability of organs for cardiac transplantation, intensifying the demand for left ventricular assist devices (LVADs) as a bridge to transplantation. There is also a growing number of patients with end-stage HF who are not transplant candidates but may be eligible for long-term support with an LVAD, known as destination therapy. Due to this increasing demand, LVAD technology has evolved, resulting in transformative improvements in outcomes. Additionally, with growing clinical experience patient management continues to be refined, leading to iterative improvements in outcomes. With outcomes continuing to improve, the potential benefit from LVAD therapy is being considered for patients earlier in their course of advanced HF. We review recent changes in technology, patient management, and implant decision making in LVAD therapy.
Triple CFTR Modulator Therapy for Cystic Fibrosis
Authors: Fernando Holguin
Journal: New England Journal of Medicine (2018)

Cystic fibrosis is one of the most common life-threatening autosomal recessive disorders, affecting approximately 80,000 children and adults worldwide.1 It is caused by mutations that result in deficient or defective function of the cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel that is normally present in epithelial membranes.2 In addition to the standard symptomatic treatments for cystic fibrosis, two types of CFTR modulator have been approved for treatment. These include a potentiator (ivacaftor), which increases CFTR channel opening at the cell surface, and correctors (lumacaftor and tezacaftor), which increase the amount of CFTR protein at the cell surface.3 Individually, . . .
The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer
Authors: R.J. Lane, N.Y. Khin, C.M. Rogan, J.S. Magnussen, K. Ho-Shon, N. Pavlakis, S.J. Clarke, T.J. Hugh
Journal: Journal of Controlled Release (2018)

The prevailing paradigm of locoregional chemotherapy has been centred around delivering chemotherapy as close to the tumour as possible and in some cases incorporating vascular isolation techniques. Strategically, the development of these techniques has been rudimentary without consideration for the interdependencies between macrovascular manipulation and the microvascular effects. This review focuses on how new capabilities offered by recent advances in vascular access technology could be exploited to facilitate the mass fluid transfer (MFT) of anticancer agents to solid tumours. A haemodynamic model of MFT is proposed using the physical laws of fluid flow, flux, and diffusion that describe the microvascular effects anticancer agents may have upon tumours through the manipulation of macrovascular blood flow control. Finally, the possible applications of this technique for several organs are discussed.
Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study
Authors: H. Gogas, I. Samoylenko, D. Schadendorf, R. Gutzmer, J.J. Grob, J.J. Sacco, K. Gorski, A. Anderson, C. Liu, J. Malvehy
Journal: Annals of Oncology (2018)
Severe chronic idiopathic neutropenia in adults : Long-term follow-up of 358 patients
Authors: A. A. na Bolyard, G. Pracht, B. Schwinzer, C. Zeidler, M. A. n Bonilla, L. Boxer, B. Chanm, J. Donadieu, C. Fier, M. Freedman, G. Kannourakis, S. E. Kinsey, J. Winkelstein, B. P. Alter, L. Reeves, K. Welte, D. C. Dale
Journal: Blood (2003)
Clinical courses of peritoneal and pleural malignant mesothelioma, a single-center experience
Authors: Masako Asayama, Hiroki Hara, Shoichi Miyazawa, Tomohiro Matsushima, Naoki Takahashi, Satoshi Shimizu, Yosuke Kumekawa, Takako Yoshii, Naomi Onda, Yutaka Takahara, Yuki Yamane, Hideaki Mizutani, Futoshi Kurimoto, Hiroshi Sakai
Journal: Annals of Oncology (2018)
Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): A qualitative study.
Authors: Heather Gelhorn, Sandra Tong, Grant Maclaine, John H. Healey, Susan V. Bukata, Vicki Leigh Keedy, Stephen Patrick Anthony, Andrew J Wagner, Daniel D. Von Hoff, Arun S. Singh, Carlos Becerra, Jennifer Hanlon, William Lenderking, Lindsey Murray, Henry H Hsu, Paul S. Lin, William D. Tap
Journal: Journal of Clinical Oncology (2015)

10521 Background: Tenosynovial giant cell tumor (TGCT), a rare locally aggressive neoplasm of the synovium of joints and tendon sheaths, is associated with inflammation, pain and swelling in part due to CSF1R-bearing macrophages recruited to the tumor by genetic elevation of CSF1 activity. Most common treatment is surgery; pharmacological treatments are in development. Patient Reported Outcome (PRO) instruments are potential critical endpoints to demonstrate treatment benefit in clinical trials. Symptoms and other PROs meaningful to TGCT patients have not been formally researched, and instruments to evaluate such outcomes do not exist. Methods: PRO instruments of potential relevance were evaluated by literature review and by clinical and PRO experts. TGCT patients were recruited through clinical sites and the internet for participation in qualitative research interviews to identify predominant symptoms and to test relevance and content validity of selected PRO measures. Results: 22 subjects participated: 73% female, mean age 42.5 (range 27-56); 19 (86%) diffuse, 3 (14%) localized TGCT; 50% prior surgery. Tumors were located in knee (n = 15), hip (n = 3), ankle (n = 2), elbow (n = 1), forearm (n = 1). Most common symptoms cited were pain (82%), stiffness (73%), swelling (86%), reduced range of motion (64%) and joint instability (64%), which were consistent with clinical expert input and with instruments chosen by PRO experts. The Brief Pain Inventory (BPI) worst pain numeric rating scale (NRS), PROMIS physical functioning items and WOMAC items identified from the literature, as well as a worst stiffness NRS developed for TGCT, were confirmed as meaningful measures of TGCT patient symptoms and were well understood in qualitative interviews. These measures are currently being piloted in an ongoing Ph1 clinical trial of PLX3397, a small molecule inhibitor of CSF1 receptor kinase, in TGCT (NCT01004861). Conclusions: Pain, stiffness and physical functioning are important treatment outcomes in TGCT patients. We have identified potentially reliable and valid PRO measures of these concepts, which are being tested in phase I and will be further evaluated in a phase III TGCT clinical trial with PLX3397. Clinical trial information: NCT01004861.
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer
Authors: Sara Redaelli, Monica Ceccon, Marina Zappa, Geeta G. Sharma, Cristina Mastini, Mario Mauri, Marion Nigoghossian, Luca Massimino, Nicoletta Cordani, Francesca Farina, Rocco Piazza, Carlo Gambacorti-Passerini, Luca Mologni
Journal: Cancer Research (2018)

Abstract Targeted therapy changed the standard of care in ALK-dependent tumors. However, resistance remains a major challenge. Lorlatinib is a third-generation ALK inhibitor that inhibits most ALK mutants resistant to current ALK inhibitors. In this study, we utilize lorlatinib-resistant anaplastic large cell lymphoma (ALCL), non–small cell lung cancer (NSCLC), and neuroblastoma cell lines in vitro and in vivo to investigate the acquisition of resistance and its underlying mechanisms. ALCL cells acquired compound ALK mutations G1202R/G1269A and C1156F/L1198F in vitro at high drug concentrations. ALCL xenografts selected in vivo showed recurrent N1178H (5/10 mice) and G1269A (4/10 mice) mutations. Interestingly, intracellular localization of NPM/ALKN1178H skewed toward the cytoplasm in human cells, possibly mimicking overexpression. RNA sequencing of resistant cells showed significant alteration of PI3K/AKT and RAS/MAPK pathways. Functional validation by small-molecule inhibitors confirmed the involvement of these pathways in resistance to lorlatinib. NSCLC cells exposed in vitro to lorlatinib acquired hyperactivation of EGFR, which was blocked by erlotinib to restore sensitivity to lorlatinib. In neuroblastoma, whole-exome sequencing and proteomic profiling of lorlatinib-resistant cells revealed a truncating NF1 mutation and hyperactivation of EGFR and ErbB4. These data provide an extensive characterization of resistance mechanisms that may arise in different ALK-positive cancers following lorlatinib treatment. Significance: High-throughput genomic, transcriptomic, and proteomic profiling reveals various mechanisms by which multiple tumor types acquire resistance to the third-generation ALK inhibitor lorlatinib.
小儿肥大细胞增多症:一项为期 12 年的随访队列研究
Authors: C. Meni, S. Georgin-Lavialle, L. Le Saché de Peufeilhoux, J.P. Jais, S. Hadj-Rabia, J. Bruneau, S. Fraitag, K. Hanssens, P. Dubreuil, O. Hermine, C. Bodemer
Journal: British Journal of Dermatology (2018)

这项来自法国巴黎的研究追踪了 53 名患有肥大细胞增多症的儿童。在肥大细胞增多症中,体内肥大细胞(最为人所知的是它们在过敏中的作用)的数量增加,特别是在皮肤中。在儿童亚型中,肥大细胞数通常仅在皮肤中增加,并且通常认为该状况在青春期前后改善。症状包括瘙痒、皮肤肿胀和水疱,但偶尔情况下,如果大量化学信使从大量肥大细胞中释放出来,会出现全身(“系统”)症状,如潮红、腹痛、腹泻和头痛。大多数儿童都有所改善,特别是如果他们患有肥大细胞增多症超过 12 年或已达到 16 岁;6 名儿童病情恶化,只有 3 个儿童的肥大细胞增多症完全从皮肤中清除。在 11 名儿童中,这种疾病在两岁后开始,这是预测随着时间推移会发生什么的唯一因素:该组的结果更糟。全身症状趋于改善,尽管它们仅在五个孩子中完全消退,并且即使皮肤改变改善也经常持续存在。3 例病例继续发展为更广泛的肥大细胞增多症,其中一例累及骨,第二例累及骨和肝脏,第三例累及肠道。46 名儿童表现出一种名为 KIT 的基因突变,已知这种基因与肥大细胞增多症有关,但这与肥大细胞增多症的类型、或者肥大细胞增多症是否改善、持续或恶化并没有关系。
Long-Term Trends in Hypertension and Elevated Blood Pressure Among U.S. Adults, 1999 to 2016
Authors: Buyun Liu, Yangbo Sun, Guifeng Xu, Shuang Rong, Jing Zhang, Yang Du, Linda G. Snetselaar, Jennifer G. Robinson, Robert B. Wallace, Wei Bao
Journal: Journal of the American College of Cardiology (2018)
Abstract 19823: Predictors of Post Cardiac Surgery Rehabilitation Therapy in Congenital Heart Disease Patients
Authors: Ana Ubeda Tikkanen, Meena Nathan, Lynn A Sleeper, Marisa Flavin, Ana Lewis, Donna Nimec, John E Mayer, Pedro del Nido
Journal: Circulation (2016)

Introduction: Congenital heart disease (CHD) patients are at risk of motor, cognitive, speech and feeding difficulties after cardiac surgery. Rehabilitation therapy (RT) can decrease the post-surgical functional morbidity. Our goal was to describe predictors of RT in CHD patients. Hypothesis: Palliative surgery patients have greater RT needs. Methods: This is a retrospective cohort study on CHD patients < 18 years repaired on cardiopulmonary bypass (CPB) at our center from 01/01/2013 to 01/31/2015. Demographic; pre, intra and postoperative; and RT (physical, occupational, speech, feeding therapy and neurodevelopment intervention) data were collected. Case complexity was determined by STS/EACTS mortality categories (STAT) and residual lesions by Technical Performance Score (TPS). Primary outcome was need for RT, primary predictor was full vs. palliative repair. Multivariable model determined the association between RT and pre and intraoperative predictors. Results: Of 1415 subjects, 253(17.9%) had palliati...
Pathophysiology of Sickle Cell Disease
Authors: Prithu Sundd, Mark T. Gladwin, Enrico M. Novelli
Journal: Annual Review of Pathology Mechanisms of Disease (2018)

Since the discovery of sickle cell disease (SCD) in 1910, enormous strides have been made in the elucidation of the pathogenesis of its protean complications, which has inspired recent advances in targeted molecular therapies. In SCD, a single amino acid substitution in the β-globin chain leads to polymerization of mutant hemoglobin S, impairing erythrocyte rheology and survival. Clinically, erythrocyte abnormalities in SCD manifest in hemolytic anemia and cycles of microvascular vaso-occlusion leading to end-organ ischemia-reperfusion injury and infarction. Vaso-occlusive events and intravascular hemolysis promote inflammation and redox instability that lead to progressive small- and large-vessel vasculopathy. Based on current evidence, the pathobiology of SCD is considered to be a vicious cycle of four major processes, all the subject of active study and novel therapeutic targeting: ( a) hemoglobin S polymerization, ( b) impaired biorheology and increased adhesion-mediated vaso-occlusion, ( c) hemolysis-mediated endothelial dysfunction, and ( d) concerted activation of sterile inflammation (Toll-like receptor 4- and inflammasome-dependent innate immune pathways). These molecular, cellular, and biophysical processes synergize to promote acute and chronic pain and end-organ injury and failure in SCD. This review provides an exhaustive overview of the current understanding of the molecular pathophysiology of SCD, how this pathophysiology contributes to complications of the central nervous and cardiopulmonary systems, and how this knowledge is being harnessed to develop current and potential therapies.
Genetic Architecture of Primary Open-Angle Glaucoma in Individuals of African Descent
Authors: Kent D. Taylor, Xiuqing Guo, Linda M. Zangwill, Jeffrey M. Liebmann, Christopher A. Girkin, Robert M. Feldman, Harvey Dubiner, Yang Hai, Brian C. Samuels, Joseph F. Panarelli, John P. Mitchell, Lama A. Al-Aswad, Sung Chul Park, Celso Tello, Jeremy Cotliar, Rajendra Bansal, Paul A. Sidoti, George A. Cioffi, Dana Blumberg, Robert Ritch, Nicholas P. Bell, Lauren S. Blieden, Garvin Davis, Felipe A. Medeiros, Swapan K. Das, Jasmin Divers, Carl D. Langefeld, Nicholette D. Palmer, Barry I. Freedman, Donald W. Bowden, Maggie C.Y. Ng, Yii-Der Ida Chen, Radha Ayyagari, Jerome I. Rotter, Robert N. Weinreb
Journal: Ophthalmology (2018)
Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes
Authors: P.A. Fasching, M. Laible, K.E. Weber, R.M. Wirtz, C. Denkert, K. Schlombs, S. Schmatloch, O. Camara, H.J. Lück, J. Huober, T. Karn, M.T. van Mackelenbergh, F. Marme, V. Müller, C. Schem, E. Stickeler, U. Sahin, S. Loibl, M. Untch
Journal: Annals of Oncology (2018)
P3.15-14 Using Creative Co-Production to Develop a Treatment Decision Support Tool for People with Malignant Pleural Effusion
Authors: C. Grindell, R. Bec, A. Tod, R. Bhatnagar, P. Sivakumar, M. Evison, A. Morley, M. Ahmed, L. Ahmed, D. Wolstenholme
Journal: Journal of Thoracic Oncology (2018)
Abstract P293: The Association of Healthy Lifestyles and Markers of Inflammation: Results From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
Authors: Jered Linares, Thanh-Huyen T Vu, Amber Pirzada, Donghong Wu, Ramon Durazo-Arvizu, Mayra Estrella, Elva Arredondo, Jianwen Cai, Linda Gallo, Hector Gonzalez, Carmen Isasi, Frank Penedo, Yanping Teng, Martha L Daviglus
Journal: Circulation (2018)

Background: Healthy lifestyle factors (HLFs; i.e., healthy diet, ideal weight, ideal physical activity, non-smoking, moderate alcohol intake) are associated with lower risk of cardiovascular disease (CVD), while inflammatory markers such as C-reactive protein (CRP) and white blood cell (WBC) count are associated with higher risk. The association of healthy lifestyles (i.e., HLF combinations) with inflammatory markers is not well established, and has not been examined in US Hispanics/Latinos. We examined cross-sectional associations of HLFs with elevated CRP levels and WBC count in Hispanic/Latino adults. Methods: Data from 12,966 men and women ages 18-74 from the baseline HCHS/SOL were analyzed. HLFs examined were: healthy diet (highest sex-specific 40% of Alternate Heathy Eating Index 2010), ideal physical activity (moderate/ vigorous activity ≥150 min/week or vigorous activity ≥75 min/week), no current smoking, moderate alcohol intake (men ≤28g/day; women ≤14g/day) and body mass index (BMI) &lt;25 kg/m 2 . Logistic regression was used to examine associations with CRP levels &gt;3mg/l or WBC count in the highest quintile (≥8x10 9 cells/L), adjusting for demographic and socioeconomic factors, CVD risk factors, and relevant clinical factors, and accounting for the complex survey design. Results: In multivariable-adjusted analyses, higher number of HLFs (vs. 0-1 HLF) were associated with progressively lower odds of CRP &gt;3mg/l and WBC count in the 5 th quintile (p-trend &lt;0.001 for both) ( Table ). In analyses on individual HLFs, BMI &lt;25 kg/m 2 and non-smoking were associated with lower odds of CRP&gt;3mg/l (0.33, [0.28,0.40] and 0.83 [0.71,0.96]) and WBC in the highest quintile (0.74 [0.62-0.89] and 0.37 [0.32-0.44]); moderate alcohol intake and healthy diet were associated with lower odds of WBC in the highest quintile (0.63 [0.48, 0.83] and 0.76 [0.64, 0.89]) (results not tabulated). Conclusion. Higher number of HLFs, particularly ideal weight and non-smoking are associated with lower levels of CRP and WBC count.
To Prevent Cardiovascular Disease, Pay Attention to Pregnancy Complications
Authors: Jennifer Abbasi
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Review: Evidence is inconclusive on dual- vs mono-antiplatelet therapy after transcatheter aortic valve implantation
Authors: Rahul Sharma
Journal: Annals of Internal Medicine (2018)

Source Citation Al Halabi S, Newman J, Farkouh ME, et al. Meta-analysis of studies comparing dual- versus mono-antiplatelet therapy following transcatheter aortic valve implantation. Am J Cardiol. 2018;122:141-8. 29779587
Abstract 18962: The Epithelial-Mesenchymal Master Regulator Zeb1 Orchestrates the Cardiac Determinant Transcription Factor Castor Zinc Finger Protein 1 (casz1) Expression and Function in Heart Regeneration
Authors: Chiara Cencioni, Francesco Spallotta, Matteo Savoia, Johanna Heid, Federica Limana, Yuri D’Alessandra, Loretta Lazzarato, Claudia Döring, Martin L Hansmann, Roberta Fruttero, Alberto Gasco, Zhihui Liu, Carol J Thiele, Andreas M Zeiher, Carlo Gaetano
Journal: Circulation (2016)

Introduction and Hypothesis: Casz1 has been recently described as an important player during heart development in both mouse and Xenopus. In mice, Casz1 deletion is embryonic lethal at stage E17.5 ...
GP is accused of molesting dozens of patients over two decades
Authors: Clare Dyer
Journal: BMJ (2018)

A retired GP is standing trial accused of molesting dozens of female patients over more than two decades for his own sexual gratification.

Alan Tutin, now aged 70, carried out the assaults between 1981 and 2004, when he retired from Merrow Park Surgery in Guildford, Surrey, prosecuting counsel Sally O’Neill told the jury at the Central Criminal Court in London.

The patients he is accused of assaulting included a girl of nine, given a vaginal and rectal examination in 1986 that made her …